Author: Li, Jingwei; Shao, Jun; Wang, Chengdi; Li, Weimin
Title: The epidemiology and therapeutic options for the COVID-19 Cord-id: 9ei1ram3 Document date: 2020_5_28
ID: 9ei1ram3
Snippet: An outbreak of coronavirus disease 2019 (COVID-19), a disease caused by a novel pneumonia virus, has affected over 200 countries and regions worldwide. With the increasing number of patients and deaths, WHO have declared it as a global pandemic currently, indicating a third large-scale epidemic coronavirus has appeared since the emergence of severe acute respiratory syndrome coronavirus (SARS) and Middle-East respiratory syndrome (MERS) in the twenty-first century. Considering the great harm it
Document: An outbreak of coronavirus disease 2019 (COVID-19), a disease caused by a novel pneumonia virus, has affected over 200 countries and regions worldwide. With the increasing number of patients and deaths, WHO have declared it as a global pandemic currently, indicating a third large-scale epidemic coronavirus has appeared since the emergence of severe acute respiratory syndrome coronavirus (SARS) and Middle-East respiratory syndrome (MERS) in the twenty-first century. Considering the great harm it has caused, researchers throughout the world have been chasing to exploit the pathophysiology, characteristics, and potential remedies for COVID-19 to better battle the outbreak. Therefore, the current study revisits advances of the virology, epidemiology, clinical features, therapeutic options, and prevention of COVID-19. The features of asymptomatic carriers are also been explored.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and liver system: 1, 2, 3
- acute ards respiratory distress syndrome and long period: 1, 2
- acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- acute ards respiratory distress syndrome and lopinavir ritonavir benefit: 1, 2
- acute ards respiratory distress syndrome and lopinavir ritonavir group: 1
- acute ards respiratory distress syndrome and lopinavir ritonavir ribavirin: 1, 2, 3, 4
- acute ards respiratory distress syndrome and lopinavir ritonavir therapy: 1, 2, 3, 4, 5, 6
- acute ards respiratory distress syndrome and lopinavir ritonavir treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and low dosage: 1, 2
- acute ards respiratory distress syndrome and low middle: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute ards respiratory distress syndrome and low sensitivity: 1, 2, 3, 4
- acute ards respiratory distress syndrome and lung region: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and lung symptom: 1
- acute phase and adequate energy: 1
- acute phase and live virus: 1, 2, 3, 4, 5, 6
- acute phase and liver system: 1, 2, 3, 4, 5, 6, 7
- acute phase and long period: 1, 2, 3
- acute phase and lopinavir ritonavir: 1, 2, 3, 4, 5
- acute phase and lopinavir ritonavir ribavirin: 1
Co phrase search for related documents, hyperlinks ordered by date